Mosaic ImmunoEngineering (NASDAQ: CPMV) files 12b-25 notifying 10-Q delay

Rhea-AI Filing Summary

Mosaic ImmunoEngineering, Inc. submitted a Form 12b-25 notification stating it could not file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 by the prescribed deadline of May 15, 2026 (5:30 p.m. EDT).

The company cites the need for additional time, resources and effort to complete financial reporting and close procedures and expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.

Key Figures

Quarter end: March 31, 2026 Prescribed deadline: May 15, 2026 5:30 p.m. EDT Filing cure window: fifth calendar day following the prescribed due date +1 more

4 metrics

Quarter end March 31, 2026 Form 10-Q reporting period

Prescribed deadline May 15, 2026 5:30 p.m. EDT original Form 10-Q due date

Filing cure window fifth calendar day following the prescribed due date Rule 12b-25 cure period for Form 10-Q

Company contact 657-208-0890 Steven King listed in Part IV

Key Terms

Rule 12b-25, Form 10-Q, prescribed due date

3 terms

Rule 12b-25 regulatory

"could not be filed without unreasonable effort or expense"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"Quarterly Report on Form 10-Q for the quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

prescribed due date regulatory

"prescribed deadline of 5:30 p.m. EDT on May 15, 2026"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):	☐  Form 10-K	☐  Form 20-F	☐  Form 11-K	☒  Form 10-Q
	☐  Form 10-D	☐  Form N-SAR	☐  Form N-CSR

For Period Ended: March 31, 2026

☐  Transition Report on Form 10-K		☐  Transition Report on Form 20-F
☐  Transition Report on Form 11-K		☐  Transition Report on Form 10-K
☐  Transition Report on Form N-SAR

For the Transition Period Ended: ________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Mosaic ImmunoEngineering, Inc.

Full Name of Registrant:

Former Name if Applicable

9114 Adams Avenue, #202

Address of Principal Executive Office (Street and Number)

Huntington Beach, CA 92646

City, State, Zip Code

PART II - RULES 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.

Mosaic ImmunoEngineering, Inc., a Delaware corporation (the “Company”), was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) by the prescribed deadline of 5:30 p.m. EDT on May 15, 2026 because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures. The Company expects to file its Form 10-Q as soon as possible, but no later than the fifth calendar day following the prescribed due date.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Steven King		657		208-0890
(Name)		(Area Code)		(Telephone No.)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Mosaic ImmunoEngineering, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 15, 2026 By: /s/ Steven King                          Title President and CEO

3

FAQ

Why did Mosaic ImmunoEngineering (CPMV) file a Form 12b-25?

The company said it needed additional time, resources and effort to complete its financial reporting and close procedures. The notification states the delay relates specifically to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

When does CPMV expect to file the delayed Form 10-Q?

Mosaic expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date. The prescribed filing deadline referenced in the notification was May 15, 2026 at 5:30 p.m. EDT.

Who can be contacted about CPMV's late filing?

The contact listed is Steven King with phone number 657-208-0890. This person is named in Part IV as the company contact for inquiries regarding the Form 12b-25 notification.

Does the Form 12b-25 state there will be a material change in results?

The provided excerpt does not attach a narrative quantifying an anticipated change in results. The company did not include a separate explanation of anticipated operational changes or numeric estimates in the notification text.